
==== Front
Haematologica
Haematologica
HAEMA
Haematologica
0390-6078
1592-8721
Fondazione Ferrata Storti

38562076
10.3324/haematol.2023.284815
Erratum
Erratum to: Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia
Verstovsek Srdan 1
Mesa Ruben 2
Talpaz Moshe 3
Kiladjian Jean-Jacques 4
Harrison Claire N. 5
Oh Stephen T. 6
Vannucchi Alessandro M. 7
Rampal Raajit 8
Scott Bart L. 9
Buckley Sarah A. 10
Craig Adam R. 10
Roman-Torres Karisse 10
Mascarenhas John O. 11
1 MD Anderson Cancer Center, Houston, TX, USA
2 Mayo Clinic, Scottsdale, AZ, USA
3 University of Michigan, Comprehensive Cancer Center, Ann Arbor, MI, USA
4 Hôpital Saint Louis, Université Paris Diderot, Paris, France
5 Guy’s and St Thomas’ NHS Foundation Trust, London, UK
6 Washington University School of Medicine, St. Louis, MO, USA
7 University of Florence, Azienda Ospedaliera-Universitaria Careggi, Florence, Italy
8 Memorial Sloan Kettering Cancer Center, New York, NY, USA
9 Fred Hutchinson Cancer Research Center, Seattle, WA, USA
10 CTI BioPharma Inc, Seattle, WA, USA
11 Icahn School of Medicine at Mount Sinai, New York, NY, USA
S. Verstovsek srdanverstovsek@gmail.com
01 4 2024
01 4 2024
109 4 13101310
05 12 2023
05 12 2023
Copyright© 2024 Ferrata Storti Foundation
https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
==== Body
pmcAn error was published in Table 2, row 5 of our manuscript in the July issue 2022 of Haematologica.1 The number for the Pacritinib group was erroneously published as 17.9 (5/28) and should be 25.0 (19/76). The corrected Table 2 is shown here.

Corrected Table 2. Spleen volume response and modified Total Symptom Score response rates among patients randomized to pacritinib versus best available therapy by subgroup: prior exposure to a JAK2 inhibitor (including ruxolitinib) and myelofibrosis subtype (primary vs. secondary after a prior diagnosis of polycythemia vera or essential thrombocythemia).
==== Refs
References

1. Verstovsek S Mesa R Talpaz M . Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia. Haematologica. 2022;107 (7 ):1599-1607.34551507
